Aktis Oncology, a clinical-stage company developing targeted radiopharmaceuticals for cancer treatment, announced that CEO Matthew Roden will present at the BofA Securities Health Care Conference on May 13, 2026. The company focuses on a proprietary miniprotein radioconjugate platform designed to deliver radioisotopes selectively to tumors, enhancing cancer cell targeting and minimizing impact on healthy tissue. Aktis is advancing clinical programs including AKY-1189 and AKY-2519, targeting multiple solid tumors. This presentation highlights Aktis' progress and potential in expanding radiopharmaceutical therapies to broader patient populations.
US stock futures gained following a mixed market close and President Trump's approval of Nvidia's H200 AI chip sales to Chinese firms, although China has halted deliveries. Economic data showed a 0.5% rise in April retail sales and a slight increase ...
Sumitomo Forestry has finalized its acquisition of Tri Pointe Homes for $47 per share, making Tri Pointe a wholly owned subsidiary and delisting it from the NYSE. This deal expands Sumitomo Forestry's U.S. homebuilding presence to 18 states, deliveri...
Verde Resources Inc. announced its invitation to the GenZero Climate Summit 2026 in Singapore, a key event focused on advancing net zero solutions. The company aims to expand its presence in Singapore and Southeast Asia, leveraging its newly establis...
Boeing shares rose following Treasury Secretary Scott Bessent's indication of significant aircraft orders from China during President Trump's meeting with Chinese President Xi Jinping. The U.S.-China tariff dispute had previously halted Boeing delive...
INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review p...
